Using Albumin Bilirubin Index to Predict Outcomes After Variceal Bleeding in Adults with Cirrhosis

What this Trial Is About

Researchers are investigating the albumin bilirubin index to predict the risk of recurrent bleeding within three months after endoscopic treatment in patients with cirrhosis and esophagogastric variceal bleeding EGVB. The study aims to clarify how well this index can forecast bleeding outcomes, which may help guide future care for affected patients. The research is observational and sponsored by Assiut University. Participants will be observed following their endoscopic treatment without receiving additional experimental interventions. The study focuses on monitoring patients over time to evaluate the relationship between their albumin bilirubin index levels and bleeding recurrence. No specific treatments or procedures beyond standard care are assigned by the study. During the study, participants health and bleeding status will be regularly assessed to track the prevalence of variceal bleeding in those with a high albumin bilirubin index over six months. Data collection will include clinical evaluations and laboratory tests as part of routine care. The study duration and follow-up are structured to gather meaningful information on this predictive markers value.

Albumin Bilirubin Index as a Predictor of Outcome of Variceal Bleeding